AMDL (Tustin, California), a vertically integrated pharmaceutical company with major operations in China and the U.S., said it has restructured its business into three distinct divisions to better reflect the company's operational focus "on becoming a world-class, diversified pharmaceutical company."

The new divisions include an In Vitro Diagnostics (IVD) division specifically focused on accelerating AMDL's market launch for the AMDL-ELISA DR-70 (FDP) cancer test; a Cancer Therapeutics division specifically focused on accelerating research for its Combination Immunogene Therapy (CIT) technology; and a China-based Integrated Pharmaceuticals division focused on the continued manufacturing, sales and distribution of AMDL's broad range of generic, specialty and branded pharmaceutical products.

"Segmenting AMDL's operations into these three distinct divisions provides us with greater market focus, increased flexibility across our diverse product portfolio, and a solid platform to successfully execute AMDL's key business goals," said President/CEO Gary Dreher. "We've achieved significant growth in sales and gross profits over the past 18 months and believe this refinement will strengthen AMDL's long-term growth position as a leading developer, manufacturer and supplier of high-quality diagnostic and pharmaceutical products."